Ypsomed Holding AG
YPHDF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.74B
Close$
$-159.08
136.4% downside
Current Fair Value
136.4% downsideOvervalued by 136.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $5.74 Billion |
|---|---|
| Enterprise Value | $6.00 Billion |
| Annual dividend | $3.35 |
| Dividend yield | 1.14% |
| Earnings per Share | $16.31 |
| Beta | 0.81 |
| Outstanding Shares | 13,543,700 |
Return
| Return on Equity | 35.51% |
|---|---|
| Return on Assets | 19.73% |
| Return on Invested Capital | 30.67% |
Valuation & Multiples
| P/E Ratio | 23.76 |
|---|---|
| PEG | 11.78 |
| Price to Sales | 5.39 |
| Price to Book Ratio | 7.94 |
| Enterprise Value to Revenue | 5.43 |
| Enterprise Value to EBIT | 18.72 |
| Enterprise Value to Net Income | 22 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.39 |
Revenue Sources
No data
Next Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$6.16
Consensus analyst estimateRevenue Estimate
$377.34 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Ypsomed Holding AG
2,025 employees
CEO: Simon Michel
Ypsomed Holding AG, along with its affiliates, specializes in the design, production, and sale of advanced injection and infusion delivery systems for pharmaceutical and biotechnology enterprises. The company structures its activities in...